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Abstract
Cathepsin D, a lysosomal aspartic protease, has been suggested to play a role in the metastatic potential of several types
of cancer A high activated cathepsin D level in breast tumor tissue has been associated with an increased incidence of relapse
and metastasis. High levels of active cathepsin D have also been found in colon cancer, prostate cancer, uterine cancer, and
ovarian cancer. Hydroxyethyl isosteres with cyclic tertiary amine have proven to be clinically useful as inhibitors of aspartyl
proteases, such as cathepsin D and the HIV 1 aspartyl protease. Also cathepsin D has recently been associated with the
development of Alzheimer's disease. Specific proteinase inhibitors, useful in investigations of the mechanisms and pathways of
intracellular protein degradation, could lead to the development of therapeutic agents for treatment of many types of
carcinomas as well as Alzheimer's disease. The design and the synthesis of (hydroxyethyl)amine isostere inhibitors with the
cyclic tertiary amines is described. The IC- and apparent Ki values for several cathepsin D inhibitors are reported.
)0

and metastasis (Wang and Lin, 2004). In fact, blood tests
are given to many cancer patients where cathepsin D is
measured as a prognostic indicator in several cancers,
including breast cancer (Fan et al., 2004), bladder cancer
(Gontero et al., 2004), and lung cancer (Vetvicka, 2004).
The first step in the development of a new drug is the
discovery or synthesis of a library of compounds with a
desirable biological activity (Berwowitz and Katzung, 2001).
A large number of these compounds are selected for cell
studies. Many are then eliminated at this point due to
poor cell permeability. Factors such as shape, size, polarity,
solubility, lipophilicity, and pKa of the compounds effect
cell permeability. Only those compounds that prove most
effective in cell studies are carried on to animal studies. In
animal studies poor bioavailability, pharmacokinetics, or
pharmacodynamics eliminate many other compounds as
potential drug candidates. Therefore, the larger the initial
library of compounds with the desirable biological activity,
the more likely a viable drug candidate willbe found. Also,
occasionally, compounds reported in the literature to be
good inhibitors of one enzyme constitute important lead
compounds for the development of inhibitors of a different
but similar enzyme. So, the structure of reported cathepsin
D inhibitors can be lead to the design of anti-HIV-1 or
anti-malarial agents. We have, therefore, undertaken the
development of a library of cathepsin D inhibitors with
varying physical properties (solubility, pKa, etc.). The
compounds reported in this article are important additions
to our earlier work (McConnell, et. al., 2003).
The use of hydroxyethyl isosteres with cyclic tertiary
amines has lead to compounds with enhanced oral

Introduction
A number of drugs currently in clinical use exert their
action by inhibiting a specific enzyme, the target enzyme,
present either in the tissues of the individual under
treatment, or those in the invading organism. Proteolytic
enzymes (proteases) are involved in many biological
functions

and

deteriorative

diseases

(Handsley and

Edwards, 2005; Zamorano et al., 200.5). Among the most
biologically important proteases are aspartyl proteases.

Many serious medical problems, such as cardiac disease
(Soylu et al., 2004), acquired immunodeficiency syndrome
(AIDS); (Bonhoeffer et al., 2004), Alzheimer's disease
(Bornebroek and Kumar-Singh, 2004), malaria (Bjelic and
Aqvist, 2004), as well as colorectal and breast cancer
(Wiedswang et al., 2004), and pancreatic cancer (Shen et al.,
2004), either result directly from, or are characterized by,
uncontrolled aspartyl protease activity. For example, the
HIV-1 aspartyl protease, which is responsible for the
maturation of HIV into the infectious viral particles (Darke
and Huff, 1994), has become an important therapeutic
target for treatment of AIDS (Johnson et al., 2004; Harrigan
et al., 2005).
Cathepsin D 'is an aspartyl protease that is very
similar to the HIV aspartyl protease in substrate specificity.
Cathepsin Dis normally restricted to the lysosomes where it
is involved in normal protein degradation. However, high
levels of active serum cathepsin D are often found in many
cancer patients (Vetvicka, 2004), and also in patients with
advanced Alzheimer's disease (Li et al., 2004). Cathepsin D
is clearly involved in the process of tumor invasion
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bsorption (Smith et al., 1997). The (R)-hydroxyethylamine
lsert is incorporated as a key component of many clinically
sed, highly potent, HIV-1 protease inhibitors. Initially
everal compounds that contain hydroxyethyl amine
sosteres with flexible alkyl amines were developed
Beaulieu et al., 1997), but they suffered limited in vivo halfives and were not therapeutically useful. Molecular
nodeling (HYPERCHEM) has shown that a six-member
ring forming the tertiary amine is able to orient the
backbone of the inhibitor toward a bioactive conformation.
This also provides more of a non-peptide functionality
which may greatly improve the half-life of the inhibitor
in vivo. We have shown by molecular modeling that the
phenyl group of a phenyalanine-type hydroxyethylene or
hydroxyethyl amine is easily positioned in the SI site of
the HIV-1aspartyl protease (McConnell et al., 1991, 2003).
Other studies show that a bulky amine or amide might fit
reasonably well into the S 2 and S sites (Paul et al., 1995).
Therefore, we decided to synthesize compounds that
contain a peptide portion to accommodate the S,, S2,and S 3
subsites and a non-peptide hydroxyethyl isostere portion
with a cyclic tertiary amine to accommodate the S, , S2-, and
S enzyme subsites. The general structure of our synthetic
target is shown in Fig. 1.

containing 1.0 g NaCl. The organic layer was washed with
distilled water (100 mL) and dried over anhydrous
magnesium sulfate. The solvent was evaporated under
reduced pressure to give a white solid (1.127 g). The crude
product was purified by silica gel column chromatography
(2.5 cm x 60 cm length) using 60% ethyl acetate/hexanes
as the mobile phase to give 0.784 g. TLC (60% ethyl
acetate/hexanes) Rf =0.59. 'H NMR (CDC13/TMS, 200
MHz) fi0.9895 (9H, s), 1.653 (2H, t), 2.255 (8H, t), 2.445
(2H, d), 3.845 (1H, d of t), 4.3821 (1H, m), 5.015 (1H, m,
exchangable), 7.115 (5H,s).
3-(5)-BOC-amino-4-phenyl-l-Af-phenylpiperazine2-(£)-butanol (lb). A solution of 3-(<S)-/-butoxycarbonyl
(BOC) amino-4-phenyl-2-(/?)-oxirane (McConnell et al.,
2003); (1.0 g, 3.1 mmol) in 100 mL dry THF was treated
with 3.25 g (20 mmol) N-phenylpiperazine. The solution
was refluxed for 48 hrs. The mixture was then cooled to
room temperature, concentrated under reduced pressure to
about one half its volume, and partitioned between ethyl
acetate (200 mL) and 5% aqueous sodium potassium
tartarate (200 mL) containing 1.0 g NaCl. The organic layer
was washed with distilled water (100 mL) and dried over
anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure to give a white solid (0.837 g). The
crude product was purified by silica gel column
chromatography (2.5 cm x 60 cm length) using 60% ethyl
acetate/hexanes as the mobile phase to give 0.663 g.
TLC (50% ethyl acetate/hexanes) Rr = 0.45. 'H NMR
(CDC13/TMS, 200 MHz) 13 1.003 (9H, s), 1.685 (2H, t),
2.338 (4H, t), 2.498 (2H, d), 2.691 (4 H, t), 3.892 (1H, d of
t), 4.491 (1H, m), 4.925 (1H, m, exchangable), 7.135 (5H,s),
7.367 (5 H, s).

:)

|

Materials and Methods
All reagents were purchased from either Aldrich,
Sigma, or Bachem Chemical Company. Anhydrous solvents
were "anhydrous grade" from Aldrich Chemical Company.
Dry solvents were distilled from sodium just prior to
use. All other solvents were HPLC grade. Thin layer
chromatography (TLC) was run on Whatman PE SIL
G/UV 250um silica gel plates. Column chromatography
was run on either Aldrich TLC grade silica gel 2-25um
particle size with average pore diameter 60D or Sigma
Sephadex LH-20, lipophilic, bead size 20- 100pm. The 'H
NMR spectra were collected either on a Bruker 200 MHz
AC 200 superconducting spectrometer or on a Hitachi 60
MHz R1200 RS NMR spectrometer. 'H NMR of final
compounds and major intermediates were collected on the
200 MHz spectrometer, while the spectra of minor
intermediates were collected on the 60 MHz NMR
spectrometer. The spectral data were processed by
NTNMR software produced by TeleMag.
3-(S)-BOCamino-4-phenyl-l-iV-piperazine-2(S)butanol (la). A solution of 3-(5)-/-butoxycarbonyl (BOC)
amino-4-phenyl-2-(/2)-oxirane (McConnell et al., 2003); (1.0
g, 3.1 mmol) in 100 mL dry THF was treated with 0.861 g
(10 mmol) piperazine. The solution was refluxed for 48 hrs.
The mixture was then cooled to room temperature,
concentrated under reduced pressure to about one half its
volume, and partitioned between ethyl acetate (200 mL)
and 5% aqueous sodium potassium tartarate (200 mL)

3-(£)-BOC-amino-4-phenyl-l-Ar-(p-nitrophenyl)
piperazine-2-(5)-butanol (lc). A solution of 3-(<S)-/-butoxycarbonyl(BOC) amino-4-phenyl-2-(/?)-oxirane (McConnell
et al., 2003); (1.0 g, 3.1 mmol) in 125mL dry THF was
treated with 5.18 g (25 mmol) l-(4-nitro-phenyl)piperazine.
The solution was refluxed for 48 hrs. The mixture was then
cooled to room temperature, concentrated under reduced
pressure to about one half its volume, and partitioned
between ethyl acetate (200 mL) and 5% aqueous sodium
potassium tartarate (200 mL) containing 1.0 g NaCl. The
organic layer was washed with distilled water (100 mL) and
dried over anhydrous magnesium sulfate. The solvent was
evaporated under reduced pressure to give a white solid
(0.717 g). The crude product was purified by silica gel
column chromatography (2.5 cm x 60 cm length) using 60%
ethyl acetate/hexanes as the mobile phase to give 0.588 g.
TLC (60% ethyl acetate/hexanes) Rf = 0.53. 'H NMR
(CDC13/TMS, 200MHz)B 1.002 (9H, s), 1.639 (2H, t), 2.445
(4H, t), 2.501 (2H, d), 3.081 (4 H, t), 3.892 (1H, m), 4.531
(1H, m), 5.035 (1H, m, exchangable), 7.105 (5H,s), 7.557 (2
H, d), 8.015 (2H, d).

S-^-amino^-phenyl-l-Af-piperazine^-^-butanol
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dihydrochloride (2a). 0.50 g of la was dissolved in 100 mL
cold (0°C) 4 MHC1 in chloroform. The mixture was stirred
at 0°C for 1 hour. Cold diethyl ether (300 mL) was added to
induce precipitation of the product. The liquid was
decanted, and the precipitant was washed twice with cold
ether (150 mL). The crude solid was dissolved in 25 mL
methanol and then recrystallized by the addition of 300 mL
cold ether. The white solid was again washed twice with
cold ether (150 mL) and dried under reduced pressure (0.44
g). TLC (10% ethanol/ethyl acetate) Rf =0.38. 'H NMR
(D2O, 60MHz) B 1.9 (2H, t), 2.9 (8H, m), 3.2 (2H, d ), 3.7
(1H, m), 4.4 (1H, m), 7.1 (5H,s).

stirred overnight

at room temperature.

The mixture was

partitioned between the layers of ethyl acetate (250 mL) and
0.01 Maqueous NaOH. The organic layer was removed and
saved. The aqueous layer was extracted again with another
250 mL ethyl acetate. The organic layers were pooled,
washed with distilled water (100 mL), dried over anhydrous
magnesium sulfate, and evaporated under reduced pressure.

3-(5)-[Cbz-L-alanyl-L-phenylalanylamino]-4-phenyll-AT-piperazine-2-(5)-butanol hydrochloride (3a). 0.162
g. TLC (15% ethanol/ethyl acetate) R, = 0.19. 'H NMR
(DMSO-d (i60 MHz) B 1.9 (4H, m), 2.5 (2H, d), 2.9 (8 H, m),
3.1 (2H, d ), 3.7 (1H, m), 4.6 (3H, m), 5.1 (1H, m), 5.4 (2H,
s), 6.8 (5H, s), 7.1 (5H,s), 7.4 (5H, s).

-

3-(5)-amino-4-phenyl-l-A^phenylpiperazine-2-(iS)butanol dihydrochloride (2b). 0.55 g of lb was dissolved
in 100 mL cold (0°C) 4 MHC1 in chloroform. The mixture
was stirred at 0°C for 1 hour. Cold diethyl ether (300 mL)
was added to induce precipitation of the product. The liquid
was decanted, and the precipitant was washed twice with
cold ether (150 mL). The crude solid was dissolved in 20 mL
methanol and then recrystallized by the addition of 300 mL
cold ether. The white solid was again washed twice with
cold ether (150 mL) and dried under reduced pressure (0.43
g). TLC (10% ethanol/ethyl acetate) Rf = 0.43. 'H NMR
(D2O, 60MHz) B 2.0 (4H, t), 2.7 (8H, m), 3.0 (2H, d ), 3.8
(1H, m), 4.4 (1H, m), 7.1 (5H,s).

-

3 (5} [Cbz-L-valy1-L-pheny lalany lamino] -4-pheny 1l-iV-piperazine-2-(,S)-butanol hydrochloride (3b). 0.125
g. TLC (15% ethanol/ethyl acetate) R, = 0.27. 'H NMR
(DMSO-d 60 MHz) B 1.3 (6H, d), 1.9 (4H, t), 2.5 (3, m), 2.7
(2H, d), 2.9 (8H, m), 3.2 (2H, d), 3.7 (1H, m), 4.6 (3H, m),
5.0 (1H, m), 5.4 (2H, s), 6.8 (5H, s), 7.1 (5H,s), 7.4 (5H, s).
()

3-(5)-[Cbz-L-leucyl-L-phenylalanylamino]-4-phenyll-7V-piperazine-2-(iS)-butanol hydrochloride (3c). 0.131 g.
TLC (15% ethanol/ethyl acetate) R, = 0.34. 'H NMR

(DMSO-d (i 60 MHz) B 1.3 (6H, d), 1.8 (4H, m), 1.9 (3H, m),
2.7 (2H, d), 3.0 (8H, m), 3.2 (2H, d ), 3.7 (1H, m), 4.6 (3H,
m), 5.0 (1H, m), 5.4 (2H, s), 6.9 (5H, s), 7.3 (5H,s), 7.5
(5H, s).

3-(5')-amino-4-phenyl-l-A^-(j&-nitrophenyl)
piperazine-2-(S)-butanol dihydrochloride (2c). 0.53 g of
lc was dissolved in 100 mL cold (0°C) 4 M HC1 in
chloroform. The mixture was stirred at 0°C for 1 hour. Cold
diethyl ether (300 mL) was added to induce precipitation of
the product. The liquid was decanted, and the precipitant
was washed twice with cold ether (150 mL). The crude solid
was dissolved in 20 mL methanol and then recrystallized by
the addition of 300 mL cold ether. The white solid was again
washed twice with cold ether (150 mL) and dried under
reduced pressure (0.45 g). TLC (10% ethanol/ethyl acetate)
Rf = 0.26. 'H NMR (D2O, 60MHz) 6 2.0 (4H, t), 2.8 (8H,
m), 3.1 (2H, d), 3.8 (1H, m), 4.4 (1H, m), 7.1 (5H,s), 7.6 (2H,
d), 8.1 (2H, d).
General Procedure for Coupling Cbz-dipeptide to
3-(iS)-amino-4-phenyl-l-Af-piperazine (iV-phenyl pipera(3ak).
zine or Af-/>-nitropnenylpiperazine)-2-(<S)-butanol
A precooled solution (-150°C) of the appropriate carbobenzoxy-dipeptide (Sigma) (0.35 mmol) in 10 mL
anhydrous DMF was treated with 56 uL (0.40 mmol)
triethyl amine. The mixture was allowed to react at -150°C
for 30 minutes and was then treated with 34 uL (0.35 mmol)
ethyl chloroformate. The mixture was stirred under N,L
atmosphere for 1 hour at -150°C. A precooled (0°C) solution
containing 0.32 mmole of either 2a, 2b, or 2c in 25 mL
anhydrous DMFand 125uL (1.0 mmole) triethyl amine was
then added to the mixed anhydride of the Cbz-dipeptide.
The combined mixture was stirred under N2 at 0°C for
4 hours, allowed to warm to room temperature, and

3-(£)-[Cbz-L-leucyl-L-leucyl]-4-phenyl-l -Npiperazine-2-(5)-butanol hydrochloride (3d). 0.145 g.
TLC (15% ethanol/ethyl acetate) R, =0.43. 'H NMR
(DMSO-d,, 60 MHz)B 1.4 (12H, d), 1.7 (6H, m), 1.9 (2H, d),
2.9 (8H, m), 3.1 (2H, d), 3.7 (1H, m), 4.5 (3H, m), 4.8 (1H,
m), 5.3 (2H, s), 7.0 (5H, s), 7.3 (5H, s).
3- (S) [Cbz-L-alanyl-L-phenylalanylamino] -4-phenyll-iV-phenylpiperazine-2-(.S)-butanol hydrochloride (3e).
0.122 g. TLC (18% ethanol/ethyl acetate) R,=0.21. 'H NMR
(DMSO-d , 60 MHz)6 1.9 (4H, m), 2.3 (3H, d), 3.0 (10H, d),
3.7 (1H, m), 4.5 (3H, m), 4.8 (1H, m), 5.4 (2H, s), 6.8 (5H, s),
7.1 (5H,s), 7.5 (5H, s), 7.9 (5H, s).
3-(5)-[Cbz-L-valyl-L-phenylalanylamino]-4-phenyll-iV-phenylpiperazine-2-(,S)-butanol hydrochloride (3f).
0.115 g. TLC (18% ethanol/ethyl acetate) R,=0.25. 'H NMR
(DMSO-d , 60 MHz)B 1.3 (6H, d), 2.0 (5H,mt), 3.1 (10H, m),
3.8 (1H, m), 4.7 (3H, m), 5.0 (1H, m), 5.3 (2H, s), 6.9 (5H, s),
7.2 (5H,s), 7.6 (5H, s).
(

(

3-(iS)-[Cbz-L-leucyl-L-phenylalanylamino]-4-phenyll-AT-phenylpiperazine-2-(<S)-butanol hydrochloride (3g).
0.112 g. TLC (18% ethanol/ethyl acetate) R,=0.31. 'H NMR
(DMSO-d 60 MHz)B 1.1 (6H, d), 1.5 (3H, m), 2.0 (4H, d),
3.1 (6H, m), 3.3 (4H, t ), 3.8 (1H, m), 4.7 (3H, m), 5.0 (1H,
m), 5.3 (2H, s), 6.8 (5H, s), 7.2 (5H,s), 7.6 (5H, s).
3 -(£)- [Cbz-L-leucyl-L-leucyl] -4-pheny 1-1
Af-phenylpiperazine-2-(.S)-butanol hydrochloride (3h).
0.112 g. TLC (18% ethanol/ethyl acetate) R,=0.31. 'H NMR
(DMSO-d 60 MHz) B 1.3 (12H, d), 1.6 (6H, m), 2.0 (2H, d),
(1

-

(i
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(4a). 0.56 g. TLC (l-butanol/H,O/acetic acid, 15/2/1)
Rf=0.46. 'H NMR (methanol-d4 200 MHz)B 2.071 (4H, d),
2.165 (3H, d), 2.279 (3H, s), 2.462 (4H, m), 2.992 (4H, t),
3.189 (2H, d), 3.465 (4H, t), 3.716 (1H, m), 4.610 (3H, m),
5.081 (1H, m), 6.949 (5H, s), 7.210 (5H,s).

0 (6H, m), 3.3 (4H, t ), 3.7 (1H, m), 4.7 (3H, m), 5.0 (1H,
i), 5.3 (2H, s), 6.9 (5H, s), 7.3 (5H,s), 7.6 (5H, s).

3-(«S)-[Cbz-L-alanyl-L-phenylalanylamino]-4-phenyl-A^-(/»-nitrophenyl)piperazine-2-(5')-butanol
ydrochloride (3i). 0.102 g. TLC (20% ethanol/ethyl

cetate) Rf = 0.26. 'H NMR (DMSO-d6 60 MHz)B 2.0 (4H,
n), 2.2 (3H, d), 3.0 (6H, d ), 3.5 (4H, t), 3.7 (1H, m), 4.5 (3H,
n), 4.8 (1H, m), 5.4 (2H, s), 6.8 (5H, s), 7.1 (5H,s), 7.5 (5H,
i), 8.0 (2H, d), 8.4 (2H, d).
3- (S) [Cbz-L-valyl-L-phenylalanylamino] -4-phenyl-

3-(5)-[Acetyl-L-valyl-L-phenylalanylamino]
-4-phenyl-l-N-piperazine-2-(5)-butanol
hydrochloride
(4b). 0.49 g. TLC (l-butanol/H 2O/acetic acid, 15/2/1) Rf=

0.51. 'H NMR (methanol-d, 200 MHz)B 1.689 (6H, d),
1.989 (1H, m), 2.087 (4H, d), 2.266 (3H, s), 2.458 (4H, m),
3.099 (2H, d), 3.477 (4H, t), 3.720 (1H, m), 4.613 (3H, m),
4.999 (1H, m), 6.959 (5H, s), 7.203 (5H,s).
3 -(.S)-[Acetyl-L-leucyl-L-phenylalany lamino]
hydrochloride
-4-phenyl-l-N-piperazine-2-(,S)-butanol
(4c). 0.46 g. TLC (l-butanol/H 2 O/acetic acid, 15/2/1) R,=
0.66. 'H NMR (methanol-d, 200 MHz)B 1.298 (6H, d),
1.690 (2H, m), 1.990 (1H, m), 2.077 (4H, t), 2.199 (3H, s),
2.459 (4H, m), 3.102 (2H, d), 3.479 (4H, t), 3.721 (1H, m),
4.614 (3H, m), 4.993 (3H, m), 6.960 (5H, s), 7.213 (5H,s).

l-iV-Qb-nitrophenylJpiperazine^-^-butanol
hydrochloride (3j). 0.122 g. TLC (20% ethanol/ethyl

acetate) R, = 0.29. 'H NMR (DMSO-d6 60 MHz) 6 1.3 (6H,
d), 2.0 (5H,m), 3.0 (6H, m ), 3.5 (4H, t), 3.8 (1H, m), 4.7 (3H,
m), 5.0 (1H, m), 5.3 (2H, s), 6.9 (5H, s), 7.2 (5H,s), 7.6 (5H,
s), 8.0 (2H, d), 8.4 (2H, d).
- 3 (S) [Cbz-L-leucyl-L-phenylalany lamino] -4-phenyl-

l-iV-(j&-nitrophenyl)piperazine-2-(5')-butanol
hydrochloride (3k). 0.108 g. TLC (20% ethanol/ethyl

acetate) Rf = 0.33. 'H NMR (DMSO-d6 60 MHz) B 1.1 (6H,
d), 1.5 (3H, m), 2.0 (4H,d), 3.1 (6H, m), 3.4 (4H, t ), 3.8 (1H,
m), 4.7 (3H, m), 5.0 (1H, m), 5.3 (2H, s), 6.8 (5H, s), 7.2
(5H,s), 7.5 (5H, s), 8.1 (2H, d), 8.5 (2H, d).

3-(SHAcetyl-L-leucyl-L-leucyl]-4-phenyl-l-N-

piperazine-2-(S)-butanol hydrochloride (4d). 0.49 g.
TLC (l-butanol/H 2O/acetic acid, 15/2/1) R, =0.71. 'H
NMR (methanol-d, 200 MHz)6 1.308 (12H, d), 1.694 (4H,
m), 1.990 (2H, m), 2.077 (2H, t), 2.201 (3H, s), 2.461 (4H, m),
3.109 (2H, d), 3.519 (4H, t), 3.724 (1H, m), 4.634 (3H, m),
5.013 (3H, m), 6.977 (5H, s), 7.243 (5H,s).

3-(S)-[Cbz-L-leucyl-L-leucyl]-4-phenyl-l -N-{pnitrophenyl)piperazine-2-(5)-butanol
hydrochloride

(31). 0.912 g. TLC (20% ethanol/ethyl acetate) R, = 0.35. 'H
NMR (DMSO-d6 60 MHz) B 1.3 (12H, d), 1.6 (6H, m), 2.0
(2H, d), 3.0 (6H, m), 3.5 (4H, t ), 3.7 (1H, m), 4.7 (3H, m),
5.0 (1H, m), 5.3 (2H, s), 6.9 (5H, s), 7.3 (5H,s), 7.6 (5H, s), 8.1
(2H, d), 8.5 (2H, d).
General Procedure for Preparation of 3-{S)-

[Acetyldipeptide-amino]-4-phenyl-l-iV-piperazine

3-(.S)-[Acetyl-L-alanyl-L-phenylalanylamino]-4-

phenyl-l-N-phenylpiperazine^-^J-butanol

hydrochloride (4e). 0.61 g. TLC (l-butanol/H 2O/acetic
acid, 15/2/1) R( = 0.58. 'H NMR (methanol-d, 200 MHz)B
1.999 (4H, d), 2.155 (3H, d), 2.315 (3H, s), 3.156 (2H, d),
3.257 (4H, d), 3.431 (4H, t), 3.715 (1H, m), 4.615 (3H, m),
4.998 (3H, m), 6.999 (5H, s), 7.242 (5H,s), 8.045 (5H, s).

(or

phenylpiper azine or />-nitrophenylpiperazine)-2-(5)butanol hydro chloride (4a-l). A solution of the
carbobenzy protected compound (3a-l); (0.20 mmol) in 250
mL methanol and 1 mL 0.01 M aqueous HC1 was treated
with 0.050 g pre-moistened 10% Pd-C to form a slurry in a
3 neck flask. H2 gas was bubbled ( 1 atm) through the rapidly
stirring mixture at room temperature for 3 hours. The
mixture was then filtered to remove the catalyst, and the
solvent was evaporated under reduced pressure. The crude
amine hydrochloride was dissolved in 15 mL dimethyl
sulfoxide (DMSO) and treated with 125 uL (0.10 mole)
triethyl amine. The mixture was stirred at room temperature
for 30 minutes. Acetic anhydride (95 uL, 1.0 mmol) was
added, and the mixture was stirred overnight at room
temperature. Cold diethyl ether (250 mL) was added to
precipitate the product. The liquid was decanted, and the
white solid was washed three times with cold ether (200
mL). The crude product was purified by Sephadex LH-20
column chromatography (column size 5 cm dia. x 80 cm)
using methanol as the mobile phase.
3 -(,S)-[Acetyl-L-alanyl-L-phenylalany lamino]
4-phenyl-l-iV-piperazine-2-(5)-butanol hydrochloride

S-^-fAcetyl-L-valyl-L-phenylalanylamino]^-

phenyl-l-N-phenylpiperazine^-^J-butanol

hydrochloride (4f). 0.74 g. TLC (1-butanol/H^O/acetic
acid, 15/2/1) R, = 0.63. 'H NMR (methanol-d, 200 MHz)B
1.652 (6H, d), 2.009 (4H, d), 2.160 (1H, m), 2.396 (3H, s),
3.180 (2H, d), 3.264 (4H, d), 3.401 (4H, t), 3.722 (1H, m),
4.625 (3H, m), 4.999 (3H, m), 6.989 (5H, s), 7.301 (5H,s),
8.066 (5H, s).

3-(5)-[Acetyl-L-leucyl-L-phenylalanylamino]-4phenyl-l-N-phenylpiperazine-2-(5')-butanol
hydrochloride (4g). 0.78 g. TLC (l-butanol/H 2O/acetic
acid, 15/2/1) R, = 0.69. 'H NMR (methanol-d., 200 MHz)B
1.409 (12H, d), 1.650 (6H, m), 2.020 (4H, d), 2.297 (3H, s),
3.162 (2H, d), 3.255 (4H, d), 3.411 (4H, t), 3.725 (1H, m),
4.622 (3H, m), 4.997 (3H, m), 6.996 (5H, s), 7.300 (5H,s),
8.088 (5H, s).
3- (S) [Acetyl-L-leucyl-L-leucyl] -4-phenyl- 1-N-pheny
lpiperazine-2-(5)-butanol hydrochloride (4h). 0.69 g.
TLC (l-butanol/H,O/acetic acid, 15/2/1) R, = 0.72. 'H
NMR (methanol-d, 200 MHz)B 1.308 (12H, d), 1.694 (4H,
m), 1.990 (2H, m), 2.077 (2H, t), 2.300 (3H, s), 3.261 (2H, d),
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3.375 (4H, d), 3.509 (4H, t), 3.724 (1H, m), 4.634 (3H, m),
5.013 (3H, m), 6.977 (5H, s), 7.243 (5H,s), 8.097 (5H, s).

activity was measured 4 times at 5 or more inhibitoi
concentrations. The average absorbance of each inhibitoi
concentration was utilized in the calculations of the
IC, values. Allabsorbances were within #0.002 standard
deviations from the mean for a given inhibitoi
concentration. The standard error for the linear regression
plots was in each case less than 3%. A plot of percent
inhibition versus the log of the inhibitor concentration
provided a value for the 50% inhibition concentration
(IC5o). All plots were linear through the 50% inhibition
value and have slopes ranging from 22 to 40. The apparent
inhibition constants, Ki(.,pp), were calculated (Evans et al.,
1985; McConnell et al., 1991) as Ki(ttpp)= IC,0 - 0.5[E0], where
[Eo] is the enzyme concentration.

S-^-fAcetyl-L-alanyl-L-phenylalanylamino]
-4-phenyl-l-A^(p-nitrophenyl)piperazine-2-(,S)-butanol
hydrochloride (4i). 0.45 g. TLC (1-butanol/H^O/acetic

()

acid, 15/2/1) Rf = 0.42.

1.999
3.257
4.998
8.444

'H NMR (methanol-d 4 200 MHz)B
(4H, d), 2.155 (3H, d), 2.315 (3H, s), 3.156 (2H, d),
(4H, d), 3.491 (4H, t), 3.715 (1H, m), 4.615 (3H, m),
(3H, m), 6.999 (5H, s), 7.242 (5H,s), 8.055 (2H, d),
(2H, d).

3-(,S)-[Acetyl-L-valyl-L-phenylalanylainino]-4phenyl-l-Af-^-nitrophenylJpiperazine^-^-butanol
hydrochloride (4j). 0.55 g. TLC (l-butanol/H,O/acetic
acid, 15/2/1) R, = 0.43. 'H NMR (methanol-d 4 200 MHz)B
1.652
3.180
4.625
8.077

(6H, d), 2.009 (4H, d), 2.160 (1H, m), 2.396 (3H, s),
(2H, d), 3.264 (4H, d), 3.500 (4H, t), 3.722 (1H, m),
(3H, m), 4.999 (3H, m), 6.989 (5H, s), 7.301 (5H,s),
(2H, d), 8.467 (2H, d)

Results and Discussion

.

Our synthetic plan of the potential cathepsin D
inhibitors involved two phases: (a) preparation of the
protected hydroxyethyl amine isostere portion and (b)
condensation and deblocking of the peptide and nonpeptide portions. The hydroxyethyl amine isosteres were
prepared from a tert-butoxycarbonyl-(BOC) chiral amino
aminoalkyl epoxide reported earlier (McConnell et al.,
2003). Similar chiral aminoalkyl epoxides (with opposite
stereochemistry) have been used successfully in the
preparation of several HIV-1aspartyl protease inhibitors
with hydroxyethyl amine isosteres (Fassler et al., 1996;
Barrish et al., 1994). The 2S,3S epoxide is utilized to prepare
HIV-1 protease inhibitors with the desired 7?-hydroxyethyl
amine isostere (Fassler et al., 1996; Barrish et al., 1994).
However, since the
amine isostere is
reported to be the more active isomer for cathepsin
D inhibition (Kick et al., 1997), we utilized the 2R,3S
protected amino epoxide in our synthesis (Scheme 1). Either
piperazine, TV-phenyl piperazine, or A^jfr-nitrophenyl)
piperazine was used as a nucleophile in the preparation of
the cyclized tertiary amines. The BOC protecting group was
removed from the primary amine with non-aqueous acid
(4 MHC1 in chloroform).
In the second phase of our synthesis, the Cbz-protected
dipeptide was condensed with ethyl chloro formate and
then reacted with the basified primary amine of the
hydroxyethyl amine isostere portion (Scheme 2). The Cbz
protecting group of the resulting compound was then
removed and replaced with an acetyl group. The final
product was purified by sephadex HP chromatography and
characterized by TLC and 'H NMR.
The twelve synthetic compounds were screened for
their cathepsin D inhibition by a spectrophotometric assay
(Yasuda et al., 1999) of hemoglobin hydrolysis (Table 1).
Modifications in the ringof the hydroxy ethyl tertiary amine
appears to have affected the potency of the inhibitors.
Those compounds with a phenyl piperazine or N-(p-

3-(.S)-[Acetyl-L-leucyl-L-phenylalanylamino]-4phenyl-l-iV-(]&-nitrophenyl)piperazine-2-(5 )-butanol
l

hydrochloride (4k). 0.56 g. TLC (l-butanol/H 2O/acetic
acid, 15/2/1) Rf = 0.45. 'H NMR (methanol-d 4 200 MHz)B
1.409 (12H, d), 1.650 (6H, m), 2.020 (4H, d), 2.297 (3H, s),
3.162 (2H, d), 3.255 (4H, d), 3.521 (4H, t), 3.725 (1H, m),
4.622 (3H, m), 4.997 (3H, m), 6.996 (5H, s), 7.300 (5H,s),
8.091 (2H, d), 8.444 (2H, d).

3-(£)-[Acetyl-L-leucyl-L-leucyl]-4-phenyl-lA^-(j&-nitrophenyl)piperazine-2-(5)-butanol

hydrochloride (41). 0.39 g. TLC (l-butanol/H 2O/acetic
acid, 15/2/1) Rf = 0.54. 'H NMR (methanol-d 4 200 MHz) 13
1.309 (12H, d), 1.695 (4H, m), 1.991 (2H, m), 2.078 (2H, t),
2.302 (3H, s), 3.261 (2H, d), 3.344 (4H, d), 3.619 (4H, t),
3.725 (1H, m), 4.635 (3H, m), 5.011 (3H, m), 6.987 (5H, s),
7.244 (5H,s), 8.099 (2H, d ), 8.455 (2H, d).
Cathepsin D Assay. The potency of compounds 4a-l was
measured as inhibitors of the cathepsin D hydrolysis of
human hemoglobin (Sigma), and the results are presented in
Table 1. Inhibition of cathepsin D was measured (Yasuda et
al., 1999) by the following method: 225 uL of the inhibitor
of appropriate concentration in sodium formate-formic acid
buffer (0.50 M,pH 3.2) and 250 uL of a 0.5% hemoglobin
solution were mixed and incubated at 450°C for 20 minutes.
Human cathepsin D (Sigma), 25 uL of a 1.0 pg/mL solution,
was added and mixed for a total enzyme concentration
of 1.1 x 10 !l M. The mixture was incubated at 450°C for
1.5 hours. The reaction was quenched by the addition of
1.0 mL cold 0.3 M trichloroacetic acid. The solution was
mixed thoroughly and then chilled in ice for 30 min to
allow separation of precipitated protein. The mixture was
centrifuged and warmed to 250°C. The liquid was decanted
into a quartz cuvette and the absorbance measured at 280
nm. The absorbance of a blank containing no enzyme was
subtracted from the reading. The inhibition of the enzyme
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(Berwowitz and Katzung, 2001), the inhibitors described in
this paper, along with our earlier work, are important
contributions to the development of a library of cathepsin D
inhibitors. Although many of our cathepsin D inhibitors will
be limited in their therapeutic usefulness, due to potential
limitations in bioavailability, with a large enough pool of
active compounds itis possible that a few of these inhibitors
may someday prove to be promising drug candidates for
the treatment of cancer. Detailed kinetic data of the
synthetic inhibitors will be determined by more sensitive
fluorometric techniques (Pimenta et al., 2001) to determine
the inhibition mechanism.

litrophenyl) piperazine ring (4e-l) show

a slightly better
athepsin D inhibition than the compounds without a
jhenyl group attached to the piperazine (4a-d). Also, the
/ariation in the TV-terminal amino acid side appears to affect
he cathepsin D inhibition. Compounds with an alanine in
ihe P:1 position, were somewhat less effective inhibitors than
those compounds with a valine or leucine in the P position.
These are general trends observed in the initial screening.
;1

Conclusions

Our synthetic route shows a great deal of promise for
future synthesis of similar hydroxyethyl amine isosteres.
'he initial screening shows our synthetic compounds to
)e potent inhibitors of cathepsin
D activity. Since a
major method for developing new drug candidates is
irough random screening of large libraries of compounds
>reviously shown to have desirable biological activity
le

Acknowledgments.-

The authors

wish to thank the
National Cancer Institute
their generous support
(Grant
2
project
of this research
No. R15 CA86933-02).
at NIHfor

Table 1. Synthetic Inhibitors
Compound Name

IC50, M

Ki(apP)» M

3(6)-[AcetyI-L-alanyl-L-phenylalanylamino]-4-phenyl-l-A^-piperazine-2(6)-butanol

5.0 x 10 7

4.28 x 10 7

No.

14a

4b 3(5)-[Acetyl-L-valyl-L-phenylalanylamino]-4-phenyl-l-A'-piperazine-2(
4c

S)-butanol

3.0

x

10''

3.38

7
x 1()

3( S)-[Acetyl-L-leucyl-L-phenylalanylamino]-4-phenyl-l-A tpiperazine-2(»S)-butanol

1.8

x

10'

1.68

x 1() 7

9.5 x 1() 7

8.28

x

1.28 x 10 7

1

l

4d 3(i)-[Acetyl-L-leucyl-L-leucylamino]-4-phenyl-l-A^-piperazine)-2( S)-butanol
4

10'

4e

3(5)-[Acetyl-L-alanyl-L-phenylalanylamino]-4-phenyl-l-A^-(A^-phenylpiperazine)-2( S)-butanol

1.3 x 10'

4f

3(5)-[Acetyl-L-valyl-L-phenylalanylamino]-4-phenyl-l-A -f (ALphenylpiperazine)-2(»S)-butanol

3.5

x 1() 7

3.38

x 1() 7

4g 3(S)-[Acetyl-L-leucyl-L-phenylalanylamino]-4-phenyl-l-A^-(A^-phenylpiperazine)-2( S)-bul.cvnol

1.8

x 1()7

1.68

7
x 1()

4h 3(5)-[Acetyl-L-leucyl-L-leucylamino]-4-phenyl-l-A^-(A^-phenylpiperazine)-2(»S)-butanol

3.5 x 10 7

1.28

x 1() 7

l

1

l

5.49x10'

4i

3(i)-[Acetyl-L-alanyl-L-phenylalanylamino]-4-phenyl-l-A'-(A^-/>-NO Lrphenylpiperazine)-2(»S)-butanol

5.5

x 10

4j

3( S)-[Acetyl-L-valyl-L-phenylalanylamino]-4-phenyl-l-A^(A^-/>-NO 1;-phenylpiperazine)-2(»S)-butanol

4.5

x

10*

4.38

4k 3(»S)-[Acetyl-L-leucyl-L-phenylalanylamino]-4-phenyl-l-A^-(N-/>-NO 2-phenylpiperazine)-2(»S)-butanol

4.(i x

10 K

4.48 x 10

41 3(i)-[Acetyl-L-leucyl-L-leucylamino]-4-phenyl-l-A^-(A^-p-NOLrphenylpiperazine)-2(6)-butanol

'
7.7 x 10 7

t

7

x 10 K

*

7.(i!) x 10 77
7.69

Spectrophotometric assays (A2K o) at pH 3.2 of cathepsin D hydrolysis of hemoglobin. Apparent inhibition constants, Kj (app),
were calculated [29] as Kj(app) =IC50 0.5 [Eo ], where [E ] is the initial enzyme concentration.
()
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